Epigral Ltd (EPIGRAL) Price & Analysis

Compare

1 Followers

EPIGRAL Stock Chart & Stats

₹1244.30

-₹4.30(-0.24%)

At close: Jan 09 4:00 PM EST

₹1244.30

-₹4.30(-0.24%)

Day’s Range― - ―

52-Week Range₹822.05 - ₹2,114.30

Previous CloseN/A

Volume42.70K

Average Volume (3M)1.86K

Market Cap

₹36.85B

Enterprise Value₹42.04B

Total Cash (Recent Filing)₹485.70M

Total Debt (Recent Filing)₹5.37B

Price to Earnings (P/E)33.6

Beta1.31

Next Earnings

Apr 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.46%

Share Statistics

EPS (TTM)9.10

Shares Outstanding43,141,340

10 Day Avg. Volume1,295

30 Day Avg. Volume1,859

Financial Highlights & Ratios

PEG Ratio0.28

Price to Book (P/B)4.21

Price to Sales (P/S)3.14

P/FCF Ratio32.61

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)58.4

Revenue Forecast (FY)₹24.75B

Bulls Say, Bears Say

Bulls Say

Profitability & MarginsEpigral reports robust gross margins and improved net margins, indicating durable operating efficiency across chlor-alkali and downstream lines. Sustained margins suggest structural pricing power in value-added products and effective cost control that supports long-term cash generation even through cycles.

Free Cash Flow RecoveryThe turn to positive free cash flow in 2025 reflects stronger operating cash conversion and reduced cash burn. Durable FCF enhances financial flexibility for capex, debt repayment or downstream integration investments, lowering refinancing risk and enabling self-funded growth over the next several quarters.

Improved Balance Sheet & ROEAn improved debt-to-equity ratio and solid ROE indicate effective capital allocation and a stronger capital structure. This durability supports resilience to industry cycles, preserves access to funding, and increases ability to invest in downstream integration that enhances long-term margin sustainability.

Bears Say

High Absolute DebtDespite improved leverage metrics, substantial absolute debt keeps financing costs and coverage risk elevated. In a cyclical chemicals business, large debt obligations can limit strategic flexibility, force higher interest expense during rate cycles, and constrain reinvestment capacity over months to years.

Revenue VolatilityReported revenue growth is volatile, with summaries noting meaningful swings year-to-year. For a capacity-driven chlor-alkali producer, volatile volumes and prices impair forward visibility, challenge normalized margin assumptions, and make multi-quarter planning and steady reinvestment more difficult.

Input Cost ExposureEpigral’s margins are structurally exposed to power and salt cost swings and to utilization rates. Persistent or rising input costs without pass-through mechanisms can compress margins across cycles, making profitability and cash flow generation sensitive to commodity and energy price trends.

Epigral Ltd News

Epigral Board Clears Q3 and Nine-Month FY25 Unaudited Results

Epigral Ltd ( ($IN:EPIGRAL) ) has provided an announcement. Epigral Limited reported that its board of directors met...

2M ago

Epigral’s Q3 Profit Slides on Margin Pressure as Capex-Led Growth Plans Stay on Track

Epigral Ltd ( ($IN:EPIGRAL) ) has shared an update. Epigral Limited reported Q3 FY26 revenue of ₹603 crore,...

2M ago

Epigral Releases Investor Presentation on Q3 FY26 Unaudited Results

Epigral Ltd ( ($IN:EPIGRAL) ) has issued an update. Epigral Limited has notified the stock exchanges that it...

2M ago

Epigral Plans One-on-One VC Meet With UTI AMC on 16 January

Epigral Ltd ( ($IN:EPIGRAL) ) has shared an update. Epigral Ltd has notified stock exchanges that it will...

2M ago

Epigral to Hold One-on-One Virtual Meeting With Bandhan Mutual Fund

Epigral Ltd ( ($IN:EPIGRAL) ) has issued an update. Epigral Limited has notified the stock exchanges that it...

3M ago

Epigral Limited Schedules Investor Meeting with VLS Finance

Epigral Ltd ( ($IN:EPIGRAL) ) has issued an announcement. Epigral Limited has announced a one-on-one meeting with VLS...

4M ago

Epigral Limited Schedules Q2 FY26 Results Conference Call

Epigral Ltd ( ($IN:EPIGRAL) ) just unveiled an announcement. Epigral Limited has announced a conference call scheduled for...

4M ago

Epigral Limited Confirms Compliance with SEBI Regulations for Q3 2025

Epigral Ltd ( ($IN:EPIGRAL) ) just unveiled an announcement. Epigral Limited has submitted a confirmation certificate under Regulation...

5M ago

Epigral Limited Releases Q1 FY26 Earnings Call Transcript

Epigral Ltd ( ($IN:EPIGRAL) ) just unveiled an announcement. Epigral Limited has released the transcript of its Q1...

7M ago

Epigral Limited Schedules Investor Meeting with EverFlow Partners

Epigral Ltd ( ($IN:EPIGRAL) ) just unveiled an update. Epigral Limited has announced a one-on-one virtual meeting with...

7M ago

EPIGRAL FAQ

What was Epigral Ltd’s price range in the past 12 months?

Epigral Ltd lowest stock price was ₹822.05 and its highest was ₹2114.30 in the past 12 months.

What is Epigral Ltd’s market cap?

Epigral Ltd’s market cap is ₹36.85B.

When is Epigral Ltd’s upcoming earnings report date?

Epigral Ltd’s upcoming earnings report date is Apr 27, 2026 which is in 39 days.

How were Epigral Ltd’s earnings last quarter?

Epigral Ltd released its earnings results on Jan 30, 2026. The company reported ₹9.1 earnings per share for the quarter, beating the consensus estimate of ₹7.3 by ₹1.8.

Is Epigral Ltd overvalued?

According to Wall Street analysts Epigral Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Epigral Ltd pay dividends?

Epigral Ltd pays a Semiannually dividend of ₹3.5 which represents an annual dividend yield of 0.46%. See more information on Epigral Ltd dividends here

What is Epigral Ltd’s EPS estimate?

Epigral Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Epigral Ltd have?

Epigral Ltd has 43,141,340 shares outstanding.

What happened to Epigral Ltd’s price movement after its last earnings report?

Epigral Ltd reported an EPS of ₹9.1 in its last earnings report, beating expectations of ₹7.3. Following the earnings report the stock price went up 0.894%.

Which hedge fund is a major shareholder of Epigral Ltd?

Currently, no hedge funds are holding shares in IN:EPIGRAL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Epigral Ltd

Epigral Limited manufactures and sells chlor-alkali and related derivatives in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resins, epichlorohydrin, chloromethanes, hydrogen peroxide, caustic soda, chlorine, hydrogen, and caustic potash products. It also trades in agrochemical products. The company serves various sectors, including CPVC pipes and fittings, windmills, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soap and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes. The company was formerly known as Meghmani Finechem Limited and changed its name to Epigral Limited in August 2023. Epigral Limited was incorporated in 2007 and is based in Ahmedabad, India.